Literature DB >> 4044796

Isolation of Capnocytophaga species with a new selective medium.

J L Rummens, J M Fossepre, M De Gruyter, H Van de Vyver, L Neyt, H W Van Landuyt.   

Abstract

A selective medium (CAP) composed of a GC agar base supplemented with 1% hemoglobin, 1% Polyvitex, and an antibiotic mixture of polymyxin B (15 U/ml), vancomycin (5 micrograms/ml), trimethoprim (2.5 micrograms/ml), and amphotericin B (2.5 micrograms/ml) was compared with another selective medium (TBBP) and two nonselective media--a blood agar and a chocolate agar--to isolate Capnocytophaga species from 725 clinical specimens. These included sputa (467 specimens), throat swabs (116 specimens), oral ulcerations (35 specimens), and periodontal pockets (107 specimens). The recovery rate of Capnocytophaga species was significantly higher with the CAP medium (96%) than with the selective TBBP medium (52.2%), the nonselective blood agar (6.2%), and the chocolate agar (4.6%). Growth of the normal flora was best inhibited on CAP medium. Colony size and yellow-brown pigment formation were maximally expressed on chocolate agar and CAP medium, but gliding motility was mostly absent. We conclude that the CAP medium is an excellent medium for the recovery of Capnocytophaga species from contaminated clinical specimens.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4044796      PMCID: PMC268413          DOI: 10.1128/jcm.22.3.375-378.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Capnocytophaga: new genus of gram-negative gliding bacteria. IV. DNA base composition and sequence homology.

Authors:  B L Williams; B F Hammond
Journal:  Arch Microbiol       Date:  1979-07       Impact factor: 2.552

2.  Septicemia due to Capnocytophaga (Bacteroides ocharaceus) in Hodgkin's disease.

Authors:  P C Appelbaum; J O Ballard; M E Eyster
Journal:  Ann Intern Med       Date:  1979-04       Impact factor: 25.391

3.  Capnocytophaga: new genus of gram-negative gliding bacteria. II. Morphology and ultrastructure.

Authors:  S C Holt; E R Leadbetter; S S Socransky
Journal:  Arch Microbiol       Date:  1979-07       Impact factor: 2.552

4.  Studies of the microbiology of periodontosis.

Authors:  M G Newman; S S Socransky; E D Savitt; D A Propas; A Crawford
Journal:  J Periodontol       Date:  1976-07       Impact factor: 6.993

5.  Capnocytophaga infection: a risk in the immunocompromised host.

Authors:  J L Rummens; C Verfaillie; A Louwagie; J Boelaert; H W Van Landuyt
Journal:  Acta Clin Belg       Date:  1984       Impact factor: 1.264

6.  Rapid identification of Capnocytophaga isolated from septicemic patients.

Authors:  J E Kristiansen; A Bremmelgaard; H E Busk; O Heltberg; W Frederiksen; T Justesen
Journal:  Eur J Clin Microbiol       Date:  1984-06       Impact factor: 3.267

7.  Septic arthritis involving Capnocytophaga ochracea.

Authors:  R E Winn; W F Chase; P W Lauderdale; F K McCleskey
Journal:  J Clin Microbiol       Date:  1984-04       Impact factor: 5.948

8.  Detection, identification, and comparison of Capnocytophaga, Bacteroides ochraceus, and DF-1.

Authors:  M G Newman; V L Sutter; M J Pickett; U Blachman; J R Greenwood; V Grinenko; D Citron
Journal:  J Clin Microbiol       Date:  1979-10       Impact factor: 5.948

9.  Capnocytophaga: new genus of gram-negative gliding bacteria. I. General characteristics, taxonomic considerations and significance.

Authors:  E R Leadbetter; S C Holt; S S Socransky
Journal:  Arch Microbiol       Date:  1979-07       Impact factor: 2.552

10.  Capnocytophaga: new genus of gram-negative gliding bacteria. III. Physiological characterization.

Authors:  S S Socransky; S C Holt; E R Leadbetter; A C Tanner; E Savitt; B F Hammond
Journal:  Arch Microbiol       Date:  1979-07       Impact factor: 2.552

View more
  1 in total

1.  In vitro susceptibility of Capnocytophaga species to 29 antimicrobial agents.

Authors:  J L Rummens; B Gordts; H W Van Landuyt
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.